Literature DB >> 23246059

Long-term prognosis of ascending aortic aneurysm after aortic valve replacement for bicuspid versus tricuspid aortic valve stenosis.

Evaldas Girdauskas1, Kushtrim Disha2, Michael A Borger3, Thomas Kuntze2.   

Abstract

OBJECTIVE: The bicuspid aorta is thought to have a higher risk of progressive dilation after aortic valve replacement with a subsequently increased risk of adverse aortic events. Our aim was to compare the risk of late aortic events after isolated aortic valve replacement surgery for bicuspid versus tricuspid aortic valve stenosis with concomitant mild to moderate dilatation of the proximal aorta.
METHODS: A total of 325 consecutive patients (60% males; mean age, 59.5 ± 10 years) with aortic valve stenosis and concomitant ascending aortic dilatation of 40 to 50 mm underwent isolated aortic valve replacement from 1995 through 2000. A total of 153 patients (47%) were diagnosed with bicuspid aortic valve stenosis (bicuspid aortic valve group), whereas the remaining 172 patients (53%) had tricuspid aortic valve stenosis (tricuspid aortic valve group). Follow-up (3566 patient-years) was 100% complete. Adverse aortic events were defined as the need for proximal aortic surgery or the occurrence of aortic dissection/rupture or sudden death during follow-up.
RESULTS: Overall survival was 78 ± 4% in the bicuspid aortic valve group versus 55 ± 6% in the tricuspid aortic valve group (P = .006) at 15 years postoperatively, but age-adjusted survival was not significantly different between groups (P = .4). A total of 5 patients (3%) in the bicuspid aortic valve group versus 9 patients (5%) in the tricuspid aortic valve group underwent proximal aortic surgery during follow-up. Aortic dissection occurred in 3 patients in the tricuspid aortic valve group and in no bicuspid aortic valve patients. Fifteen-year freedom from adverse aortic events was 93 ± 3% in the bicuspid aortic valve group versus 82 ± 6% in the tricuspid aortic valve group (P = .2).
CONCLUSIONS: Patients with bicuspid and tricuspid aortic valve stenosis with concomitant mild to moderate ascending aortic dilatation are at comparably low risk of adverse aortic events 15 years after isolated aortic valve replacement.
Copyright © 2014 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.

Entities:  

Keywords:  20.2; 26.1; 35.2; 35.3; AVR; BAV; TAV; aortic valve replacement; bicuspid aortic valve; tricuspid aortic valve

Mesh:

Year:  2012        PMID: 23246059     DOI: 10.1016/j.jtcvs.2012.11.004

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  23 in total

1.  Late post-AVR progression of bicuspid aortopathy: link to hemodynamics.

Authors:  Shiho Naito; Tatiana Gross; Kushtrim Disha; Yskert von Kodolitsch; Hermann Reichenspurner; Evaldas Girdauskas
Journal:  Gen Thorac Cardiovasc Surg       Date:  2017-02-13

2.  Combination of a Giant Dissected Ascending Aortic Aneurysm with Multiple Fistulae into the Cardiac Chambers Caused by Prosthetic Aortic Valve Endocarditis.

Authors:  Feridoun Sabzi; Reza Faraji
Journal:  Sultan Qaboos Univ Med J       Date:  2016-02-02

Review 3.  Bicuspid aortic valve and aortic coarctation in congenital heart disease-important aspects for treatment with focus on aortic vasculopathy.

Authors:  Christoph Sinning; Elvin Zengin; Rainer Kozlik-Feldmann; Stefan Blankenberg; Carsten Rickers; Yskert von Kodolitsch; Evaldas Girdauskas
Journal:  Cardiovasc Diagn Ther       Date:  2018-12

Review 4.  Transcatheter aortic valve implantation in bicuspid anatomy.

Authors:  Zhen-Gang Zhao; Hasan Jilaihawi; Yuan Feng; Mao Chen
Journal:  Nat Rev Cardiol       Date:  2014-10-14       Impact factor: 32.419

5.  Functional characterization and circulating expression profile of dysregulated microRNAs in BAV-associated aortopathy.

Authors:  Silvia Pulignani; Andrea Borghini; Ilenia Foffa; Cecilia Vecoli; Lamia Ait-Alì; Maria Grazia Andreassi
Journal:  Heart Vessels       Date:  2019-09-27       Impact factor: 2.037

6.  Should the dilated ascending aorta be repaired at the time of bicuspid aortic valve replacement?

Authors:  Tsuyoshi Kaneko; Prem Shekar; Vladimir Ivkovic; Nicholas T Longford; Chuan-Chin Huang; Martin I Sigurdsson; Robert C Neely; Maroun Yammine; Julius I Ejiofor; Vanessa Montiero Vieira; Jasmine T Shahram; Karam M Habchi; Gregory W Malzberg; Peter S Martin; Jordan Bloom; Eric M Isselbacher; J Daniel Muehlschlegel; Thoralf M Sundt; Simon C Body
Journal:  Eur J Cardiothorac Surg       Date:  2018-03-01       Impact factor: 4.191

Review 7.  Bicuspid Aortic Valvulopathy and Associated Aortopathy: a Review of Contemporary Studies Relevant to Clinical Decision-Making.

Authors:  Michael H Kwon; Thoralf M Sundt
Journal:  Curr Treat Options Cardiovasc Med       Date:  2017-09

8.  Association Between Transcatheter Aortic Valve Replacement for Bicuspid vs Tricuspid Aortic Stenosis and Mortality or Stroke Among Patients at Low Surgical Risk.

Authors:  Raj R Makkar; Sung-Han Yoon; Tarun Chakravarty; Samir R Kapadia; Amar Krishnaswamy; Pinak B Shah; Tsuyoshi Kaneko; Eric R Skipper; Michael Rinaldi; Vasilis Babaliaros; Sreekanth Vemulapalli; Alfredo Trento; Wen Cheng; Susheel Kodali; Michael J Mack; Martin B Leon; Vinod H Thourani
Journal:  JAMA       Date:  2021-09-21       Impact factor: 56.272

Review 9.  Bicuspid aortic valve related aortopathy.

Authors:  Sina Stock; Salah A Mohamed; Hans-Hinrich Sievers
Journal:  Gen Thorac Cardiovasc Surg       Date:  2017-08-30

Review 10.  Surgical treatment of bicuspid aortic valve disease: knowledge gaps and research perspectives.

Authors:  Alessandro Della Corte; Simon C Body; Anna M Booher; Hans-Joachim Schaefers; Rita K Milewski; Hector I Michelena; Arturo Evangelista; Philippe Pibarot; Patrick Mathieu; Giuseppe Limongelli; Prem S Shekar; Sary F Aranki; Andrea Ballotta; Giuseppe Di Benedetto; Natzi Sakalihasan; Gianantonio Nappi; Kim A Eagle; Joseph E Bavaria; Alessandro Frigiola; Thoralf M Sundt
Journal:  J Thorac Cardiovasc Surg       Date:  2014-01-21       Impact factor: 5.209

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.